23 Jan 2023 11:15
Hardman & Co Research Hardman & Co Q&A on Shield Therapeutics (STX): Positioned for profitability with Viatris deal and its additional capital 23-Jan-2023 / 11:15 GMT/BST    Analyst interview |  Life Sciences Q&A on Shield Therapeutics (STX) | Positioned for profitability with Viatris deal and its additional capitaltive Shield Therapeutics (STX) is the topic of conversation when Dr Martin Hall joins DirectorsTalk Interviews. Martin summarises a number of announcements made by the company recently, explains Accrufer has performed in the US, a co-promotion deal with Viatris, changes made to the forecast and with the share price languishing what Martin expects to happen from here. Shield Therapeutics plc is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead medicine ACCRUFeR. Listen to the interview here  If you are interested in meeting the company, you can register your interest here
Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement. About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report. Â Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement. |
1541257 23-Jan-2023Â
corporate announcement transmitted by EQS Group AG. The issuer is solely responsible for the content of this announcement.